Trials / Completed
CompletedNCT04282954
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
A Randomized, Double-blind, Active-controlled, Multi-center Phase II Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Onconic Therapeutics Inc. · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JP-1366 | JP-1366, QD |
| DRUG | JP-1366 placebo | JP-1366 placebo, QD |
| DRUG | Esomeprazole 40mg | Esomeprazole 40mg, QD |
| DRUG | Esomeprazole placebo | Esomeprazole placebo, QD |
Timeline
- Start date
- 2019-11-15
- Primary completion
- 2020-10-20
- Completion
- 2020-12-11
- First posted
- 2020-02-25
- Last updated
- 2022-07-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04282954. Inclusion in this directory is not an endorsement.